Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
Status:
Terminated
Trial end date:
2017-07-27
Target enrollment:
Participant gender:
Summary
This is for subjects with metastatic Renal Cell Cancer (RCC). There are four Food and Drug
Administration (FDA) approved drugs for first-line therapy of Renal Cell Cancer (RCC) and two
for second-line therapy. Each of these drugs targets a specific molecular pathway. At present
oncologists select therapy based on current guidelines. There is a new method for trying to
use biomarker information from the subject's tumor to select the best drug to treat the
subject. This process is investigational, which is why this study is being done.
Biomarkers are genes, proteins and other molecules that affect how cancer cells grow,
multiply, die and respond to other compounds in the body. These biomarkers build a tumor
profile or "fingerprint" of the subject's tumor. A new focus in cancer care is personalized
treatment, where doctors select a drug based on the subject's tumor's unique "fingerprint"
which is more likely to be effective in fighting the tumor. Selecting the treatment the
subject is more likely to respond to requires a thorough understanding of the relationship
between biomarker and treatment effect. The PI wants to gather data to understand that
relationship to help treat future cancer patients. The purpose of this study is to evaluate
efficacy of treatments that are selected based on tumor profiles.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston